Biblio Discovery — Demo Discovery Service

39 hasil untuk "Michael Untch"

Menampilkan 1–20 · 0,31 detik · RSS

  1. Artikel Jurnal

    Exemestane in early breast cancer: a review

    Michael Untch; Christian Jackisch

    Therapeutics and Clinical Risk Management, Vol. 2008 No. Issue 6 · 2008 · Inggris · DOAJ Scopus

    Michael Untch1, Christian Jackisch21Interdisciplinary Breast Centre, Helios Klinikum Berlin-Buch, University Charité, Berlin, Germany; 2Department of Gynecology/Obstetrics, Klinikum Offenbach GmbH, Offenbach, GermanyAbstract: The adjuvant treatment of women with endocrine-sensitive early…

  2. Artikel Jurnal

    Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany

    Josef Rüschoff; Annette Lebeau; Peter Sinn dkk.

    Breast, Vol. 49 · 2020 · Inggris · DOAJ Scopus

    Background: The German NIU HER2 model was developed based on five variables found to have statistically significant influences on HER2-positivity, to allow exploration of deviations between model-predicted and actual HER2-positivity rates as a measure of testing quality. The prospective…

  3. Artikel Jurnal Teks lengkap

    Physiologically-Based Pharmacokinetics of Ribociclib Drug–Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer

    Yan Ji; Felix Huth; Craig Wang dkk.

    Pharmaceuticals, Vol. 19 No. 3 · 2026 · Inggris · DOAJ Scopus

    Background: Ribociclib, initially approved for HR+/HER2− advanced breast cancer (ABC) at a 600 mg dose, was recently approved for HR+/HER2− early breast cancer (EBC) at a 400 mg dose based on the NATALEE trial. Differences in dose and patient population warrant reassessment of ribociclib drug–drug…

  4. Artikel Jurnal

    Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based studyResearch in context

    Xingrong Liu; Behnaz Binicy; Balazs Acs dkk.

    The Lancet Regional Health. Europe, Vol. 59 · 2025 · Inggris · DOAJ Scopus

    Summary: Background: Nationwide studies on the prevalence, characteristics and long-term prognosis of patients with early breast cancer and a potential indication for adjuvant CDK4/6 inhibitors are lacking. Methods: We leveraged a prospectively collected nationwide cohort of all patients treated…

  5. Artikel Jurnal

    Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2− early breast cancer

    Wolfgang Janni; Michael Untch; Nadia Harbeck dkk.

    Breast, Vol. 81 · 2025 · Inggris · DOAJ Scopus

    Background: Current standard of care for patients with HR+/HER2− early breast cancer (EBC) includes adjuvant endocrine therapy with an aromatase inhibitor (AI) or tamoxifen (TAM). We present a trial-level meta-analysis on efficacy of AI vs TAM in patients with HR+/HER2− EBC. Methods: A systematic…

  6. Artikel Jurnal

    Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialResearch in context

    Alexios Matikas; Andri Papakonstantinou; Sibylle Loibl dkk.

    The Lancet Regional Health. Europe, Vol. 49 · 2025 · Inggris · DOAJ Scopus

    Summary: Background: It is unclear whether some patients with high-risk breast cancer do not warrant adjuvant dose-dense chemotherapy due to small expected absolute benefit. Methods: The phase 3 PANTHER trial (NCT00798070) compared adjuvant sequential epirubicin/cyclophosphamide (EC) and docetaxel…

  7. Artikel Jurnal Teks lengkap

    The Reality in the Surveillance of Breast Cancer Survivors—Results of a Patient Survey

    Hans-Joachim, Stemmler; Dorit, Lässig; Petra, Stieber dkk.

    Breast Cancer (Auckl) · 2008 · Inggris · PubMed Central

    BACKGROUND: International guidelines for the surveillance of breast cancer patients recommend a minimized clinical follow-up including routine history and physical examination and regularly scheduled mammograms. However, the abandonment of scheduled follow-up examinations in breast cancer survivors…

  8. Artikel Jurnal

    Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy

    David Krug; Valentina Vladimirova; Michael Untch dkk.

    Breast, Vol. 74 · 2024 · Inggris · DOAJ Scopus

    Background: Neoadjuvant chemotherapy (NACT) is routinely used for patients with triple-negative breast cancer (TNBC). Upfront breast-conserving therapy (BCT) consisting of breast-conserving surgery (BCS) and adjuvant radiotherapy (RT) has been shown to be associated with improved outcome in…

  9. Artikel Jurnal

    Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

    Ines Stevic; Volkmar Müller; Karsten Weber dkk.

    BMC Medicine, Vol. 16 No. 1 · 2018 · Inggris · DOAJ Scopus

    Abstract Background The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes of breast cancer (BC). Methods First, miRNA expression profiles were…

  10. Artikel Jurnal Teks lengkap

    Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

    Yasmin Issa-Nummer; Silvia Darb-Esfahani; Sibylle Loibl dkk.

    PLoS ONE, Vol. 8 No. 12 · 2013 · Inggris · PLOS Scopus

    Introduction: We have recently described an increased lymphocytic infiltration rate in breast carcinoma tissue is a significant response predictor for anthracycline/taxane-based neoadjuvant chemotherapy (NACT). The aim of this study was to prospectively validate the tumor-associated lymphocyte…

    Juga tersedia di: DOAJ

  11. Artikel Jurnal Teks lengkap

    Pembrolizumab for Early Triple-Negative Breast Cancer

    Peter Schmid; Javier Cortés; Lajos Pusztai dkk.

    New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of…

  12. Artikel Jurnal

    On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer

    Bruno Valentin Sinn; Katharina Sychra; Michael Untch dkk.

    Breast Cancer Research, Vol. 26 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Background Patients with pathologic complete response (pCR) to neoadjuvant chemotherapy for invasive breast cancer (BC) have better outcomes, potentially warranting less extensive surgical and systemic treatments. Early prediction of treatment response could aid in adapting therapies…

  13. Artikel Jurnal

    Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy

    Jens Huober; Marion van Mackelenbergh; Andreas Schneeweiss dkk.

    npj Breast Cancer, Vol. 9 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant GBG/AGO-B trials fulfill the inclusion criteria of this analysis. Primary endpoint…

  14. Artikel Jurnal

    Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

    Peter Schmid; Javier Cortes; Rebecca Alexandra Dent dkk.

    New England Journal of Medicine · 2024 · Inggris · OpenAlex Scopus

    BACKGROUND: In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results…

  15. Artikel Jurnal

    Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Clinical significance of micrometastases: Data from five neoadjuvant studies

    Fabienne J. Warnecke; Johannes Holtschmidt; Andreas Schneeweiss dkk.

    Breast, Vol. 89 · 2026 · Inggris · DOAJ Scopus

    Introduction: Axillary surgery for early breast cancer has become less aggressive. However, the optimal approach after neoadjuvant systemic therapy (NST) remains uncertain and depends on axillary response. Especially the significance of nodal micrometastases (ypN1mi) after NST regarding oncological…

  16. Artikel Jurnal

    Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers

    Lothar Häberle; Ramona Erber; Paul Gass dkk.

    Breast Cancer Research, Vol. 27 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Pathological complete response (pCR) is an established surrogate marker for prognosis in patients with breast cancer (BC) after neoadjuvant chemotherapy. Individualized pCR prediction based on clinical information available at biopsy, particularly immunohistochemical (IHC)…

  17. Artikel Jurnal

    Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

    Sibylle Loibl; Chiun-Sheng Huang; Max S. Mano dkk.

    npj Breast Cancer, Vol. 8 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients…